This study involves a study drug called rimegepant, which is being developed for the treatment of chronic rhinosinusitis (inflammation and swelling of the mucus membranes found in the nasal cavity and sinuses). Rimegepant is currently approved by the FDA and being used to prevent and treat the symptoms of migraine headaches in adults.
Study requires 3 visits and 1 dose of study medication.
No insurance needed. All study procedures provided at no cost. Compensation for time and travel is also provided.
Criteria:1) 18 years and older
2) Have minimum of 3 months history of facial pain, pressure, and fullness, AND one or more of the following signs and symptoms: Nasal discharge, Nasal Obstruction, or Decreased sense of smell.
3) No facial, nasal or sinus surgery within the last 6 months.